• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Young Pharmacists >Pharmacokinetic Interaction of Gliclazide with Ornidazole in Healthy Albino Wistar Rats
【24h】

Pharmacokinetic Interaction of Gliclazide with Ornidazole in Healthy Albino Wistar Rats

机译：格列齐特与奥硝唑在健康白化Wistar大鼠中的药代动力学相互作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Gliclazide is a widely used drug for the treatment of type 2 diabetes. Retrospective studies shows that diabetics are at increased risk of suffering severe complications after amoebic infection. Ornidazole is a widely used antiamoebic drug. The objective of this study was to examine the effect of oral administration of ornidazole on blood glucose levels, investigate its effect on the activity and pharmacokinetics of gliclazide in normal rats and to evaluate the safety and effectiveness of the combination. Methods: Studies in normal rats were conducted with oral doses of 2 mg/kg body weight of gliclazide and 25 mg/kg body weight of ornidazole andin combination. Blood samples were collected at regular time intervals from rat’s orbital sinuses. All the blood samples were analysed for blood glucose by glucose oxidase/peroxidase (GOD/POD) method and HPLC was used to understand the pharmacokinetics of gliclazide alone and in combination with ornidazole. Results: The results of the present study is indicating that ornidazole does not possess glucose lowering activity therefore it may be inferred that drug-drug interaction of ornidazole with gliclazide is pharmacokinetic type and the possible interaction may be due to CYP2C9 inhibition. Gliclazide produced glucose lowering activity in normal rats with peak activity at 2 h. In combination, ornidazole increases the effect of gliclazide in rats. Conclusion: Thus, it can be concluded that the combination of ornidazole and gliclazide may need slight dose adjustment and care should be taken when the combination is prescribed for their clinical benefit in diabetic patients. However, further studies are warranted.
机译：背景：格列齐特是一种广泛用于治疗2型糖尿病的药物。回顾性研究表明，糖尿病患者发生阿米巴感染后罹患严重并发症的风险增加。奥硝唑是一种广泛使用的抗贫血药物。这项研究的目的是检查口服奥硝唑对血糖水平的影响，研究其对格列齐特在正常大鼠中的活性和药代动力学的影响，并评估该组合的安全性和有效性。方法：在正常大鼠中，口服2 mg / kg体重的格列齐特和25 mg / kg的奥硝唑及其组合口服剂量进行研究。每隔一定时间从大鼠眼眶窦中采集血样。通过葡萄糖氧化酶/过氧化物酶（GOD / POD）方法分析了所有血样的血糖，并使用HPLC了解了格列齐特单独使用或与奥硝唑联用的药代动力学。结果：本研究的结果表明奥硝唑不具有降低葡萄糖的活性，因此可以推断奥硝唑与格列齐特的药物相互作用是药代动力学类型，可能的相互作用可能是由于CYP2C9抑制。格列齐特可在正常大鼠中产生葡萄糖降低活性，并在2 h达到峰值活性。联合使用奥硝唑可提高格列齐特对大鼠的作用。结论：因此，可以得出结论，奥硝唑和格列齐特的组合可能需要微调剂量，并且开具联合使用处方以使其对糖尿病患者具有临床益处时应注意。但是，需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号